ER tapentadol data in diabetic peripheral neuropathy support J&J sNDA
This article was originally published in Scrip
Executive Summary
A bid by Janssen Pharmaceuticals, a Johnson & Johnson company, to get FDA approval for the use of Nucynta ER (tapentadol) extended-release tablets in managing pain associated with chronic diabetic peripheral neuropathy (DPN) has been given a welcome boost by additional Phase III data.